NCT02906683View on ClinicalTrials.gov

Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence

PHASE2CompletedINTERVENTIONAL
Enrollment

337

Participants

Timeline

Start Date

October 20, 2016

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Stress Urinary Incontinence
Interventions
DRUG

TAS-303

Oral administration for 8 weeks, once daily.

DRUG

Placebo

Oral administration for 8 weeks, once daily.

Trial Locations (1)

Unknown

Taiho Pharmaceutical Co., Ltd selected site, Osaka

All Listed Sponsors
lead

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

NCT02906683 - Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence | Biotech Hunter | Biotech Hunter